Geode Capital Management LLC Sells 2,365 Shares of MediWound Ltd. (NASDAQ:MDWD)

Geode Capital Management LLC reduced its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 2.4% in the third quarter, Holdings Channel.com reports. The fund owned 95,302 shares of the biopharmaceutical company’s stock after selling 2,365 shares during the quarter. Geode Capital Management LLC’s holdings in MediWound were worth $1,721,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. MetLife Investment Management LLC purchased a new stake in MediWound in the third quarter worth $89,000. Rhumbline Advisers bought a new position in shares of MediWound in the second quarter worth about $131,000. Barclays PLC increased its stake in MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 8,449 shares during the period. Point72 Asset Management L.P. bought a new stake in MediWound during the 3rd quarter valued at about $212,000. Finally, Bank of New York Mellon Corp bought a new stake in MediWound during the 2nd quarter valued at about $342,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Trading Down 6.8 %

Shares of MDWD stock opened at $16.01 on Thursday. MediWound Ltd. has a twelve month low of $11.04 and a twelve month high of $24.00. The stock has a fifty day simple moving average of $17.35 and a two-hundred day simple moving average of $17.63. The stock has a market capitalization of $172.68 million, a price-to-earnings ratio of -5.52 and a beta of 0.80.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the previous year, the business earned ($0.24) earnings per share. Research analysts predict that MediWound Ltd. will post -2.6 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright dropped their target price on shares of MediWound from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.